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Background: Trials have not assessed the effect of dalfampridine-extended release (dalfampridine-ER) on health
utility. We sought to evaluate the effect of dalfampridine-ER tablets (prolonged-release fampridine in Europe) on
health utility in patients with multiple sclerosis (MS) by mapping subjects’ individual item scores from the 12-Item
Multiple Sclerosis Walking Scale (MSWS-12) onto the Euroqol 5-Dimension (EQ-5D) health utility index.
Methods: Data from study MS-F203, a randomized trial of dalfampridine-ER tablets, 10 mg twice daily, in patients
with MS, were used to calculate the health utility scores with two MSWS-12 to EQ-5D mapping equations (one
derived in a North American [NA] registry, the other a United Kingdom [UK] registry). MS-F203 participants were
categorized as dalfampridine-ER 20%-responders (achieving ≥20% improvement on the Timed 25-Foot Walk),
dalfampridine-ER 20%-nonresponders (<20% improvement), or placebo patients. Mean change in health utility
scores from baseline to each double-blind treatment evaluation (visits 3-6 occurring at post-randomization weeks 2,
6, 10, and 14) and each off-drug follow-up evaluation (visits 7-8 occurring at weeks 16 and 18) were calculated and
reported as effect sizes (ESs).
Results:
Using the NA-derived equation, dalfampridine-ER 20%-responders demonstrated improvement in health utility vs.
placebo; starting at week 6 (mean difference in ES = 0.44, p = 0.002) and maintained at weeks 10 (ES = 0.41, p = 0.01)
and 14 (ES = 0.71, p < 0.001). These improvements were no longer evident after dalfampridine-ER was discontinued
(p > 0.05 at weeks 16 and 18). Dalfampridine-ER 20%-nonresponders did not show improvement vs. placebo at any
visit (p > 0.05 for all). When using the UK-derived equation, improvement was seen in dalfampridine-ER 20%-
responders vs. placebo at weeks 2, 6, 10, and 14 (ESs = 0.49, 0.55, 0.59, and 0.99; p < 0.03 for all), but not when
dalfampridine-ER was discontinued (weeks 16 and 18; p > 0.05 for both). Dalfampridine-ER 20%-nonresponders showed
no improvement at any visit (p > 0.05 for all).
Conclusion: Regardless of the equation used, dalfampridine-ER response was associated with an improvement in
health utility.
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Multiple Sclerosis (MS), a chronic and progressive neuro-
logic disease affecting approximately 400,000 Americans,
is primarily diagnosed between the ages of 18 and 45 years
[1]. Mobility impairment is a major concern of MS pa-
tients, and data suggest that even mild mobility loss asso-
ciated with MS may adversely affect health-related quality
of life (HrQoL) [2,3].
The 12-Item Multiple Sclerosis Walking Scale (MSWS-
12) is a validated rating scale that captures patients’ per-
ceptions of the impact of MS on walking ability [4]. The
MSWS-12 was used as to validate the clinical significance
of changes in walking speed (as measured by the Timed
25-Foot Walk [T25FW]) in a Phase 3 randomized, con-
trolled trial of dalfampridine extended release tablets
(dalfampridine-ER; known as prolonged-release fampridine
in Europe and as sustained or modified release fampridine
elsewhere) in MS patients (MS-F203). Dalfampridine-ER
is an oral, broad spectrum potassium channel blocker that
is indicated to improve walking in patients with MS. In
this study, mean changes from baseline MSWS-12 score
on a 100 point scale during the 14-week double-blind
treatment period, independent of treatment assignment,
were -6.84 (95% confidence interval [CI]: -9.65 to -4.02)
for Timed 25-Foot Walk (T25FW) responders (using the
trial’s own definition of response) and 0.05 (95%CI: -1.48
to 1.57) for non-responders, (p = 0.0002), indicating a re-
duction in patient-assessed walking impairment in
T25FW responders. This trial also demonstrated that
dalfampridine-ER produced clinically meaningful im-
provement in walking speed in a proportion of people
with MS as measured by the T25FW test, regardless of
disease course or concomitant use of disease modifying
agents [5]. Despite the fact that dalfampridine-ER is a drug
to treat a symptom of MS (walking impairment) highly as-
sociated with decreased HrQoL, no data assessment of the
effect of dalfampridine-ER on a measure of health utility
or HrQoL has been published. The availability of such
data would aid decision- and policy-makers in making
coverage decisions and investigators in future research
endeavors.
Two groups have independently developed equations
to map the MSWS-12 onto the Euroqol 5-Dimension
(EQ-5D) [6], a validated, generic, preference-based health
status measure. Both equations utilize the responses from
individual items of the MSWS-12 to derive health utility
scores (measures of HrQoL); however, one equation was
derived in a large North American (NA) population [7]
and the other in a smaller United Kingdom (UK) popula-
tion [8]. As no one equation perfectly fits any population,
we used both of the aforementioned MSWS-12 to EQ-5D
mapping equations to address our primary objective which
was to evaluate the effect of dalfampridine-ER on health
utility and HrQoL.Methods
Data for these post-hoc analyses were taken from study
MS-F203 (clinicaltrials.gov registration: NCT00127530),
a Phase 3, randomized, double-blind, parallel group,
placebo-controlled, multi-center clinical trial conducted
in the US and Canada. The objective was to assess the
efficacy and safety of dalfampridine-ER to improve walk-
ing in patients with MS. The primary outcome measure
in this trial was improvement in walking speed, in feet
per second, as measured by the T25FW test during the
double-blind treatment period. Patients were screened
prior to receiving study medication; eligible patients
(those aged 18–70 years with clinically defined MS, who
were able to complete two trials of the T25FW in an aver-
age time of 8–45 seconds) returned one week later (visit
0). Patients then entered a two-week, single-blind, placebo
run-in period (visit 1 at the beginning of week 2 of placebo
run-in). At the end of the placebo run-in (visit 2), patients
were randomly assigned to receive dalfampridine-ER at a
dose of 10 mg twice daily or placebo. After two weeks, pa-
tients returned for the first double-blind assessments (visit
3). Thereafter, patients returned every four weeks for a
total of 14 weeks of double-blind treatment (visits 4, 5,
and 6 corresponding to weeks 6, 10, and 14). At the end
of the 14-week double-blind treatment period, patients
began a four-week period of no treatment, returning for
follow-up assessments at two-week intervals (visits 7 and
8 corresponding to weeks 16 and 18) [5].
A secondary outcome measure in study MS-F203 was
the MSWS-12. The MSWS-12 is a validated, patient-
reported functional outcome measure assessing patients’
perceptions of the impact of MS on their walking ability.
The MSWS-12 includes 12 questions that are rated on a
scale ranging between 1 (“Not at all”) and 5 (“Extremely”).
Each of the 12 questions asks about a different aspect of
walking, such as ability and speed of walking; ability to
run; ability to climb and descend stairs; balance and
smoothness of gait; support, effort, and concentration re-
quired. Total scores are calculated and range from 12–60,
or, to aid in interpretation, can be reported as transformed
scores ranging from 0–100. Higher scores reflect a
greater negative impact on walking ability [4]. In study
MS-F203, the MSWS-12 was assessed at visits 0, 2, 3, 4,
5, 6, 7, and 8 [5].
Two unique and independently derived mapping equa-
tions were used to cross-walk MSWS-12 individual item
scores from study MS-F203 to health utility scores using
the EQ-5D. The first equation was derived using over
3,500 participants (mean EQ-5D and MSWS-12 scores
were 0.74 ± 0.18 and 50.8 ± 33.5, respectively) in the
North American Research Committee on Multiple Scler-
osis (NARCOMS) registry using ordinary least squares
(OLS) regression and scoring the EQ-5D using the US
scoring algorithm (which ranges from -0.11 to 1.0 on a
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tion (EQ-5DUS = 0.002* [Item 1] -0.009* [Item 2] -0.01*
[Item 3] -0.029* [Item 4] -0.019* [Item 5] -0.0000881*
[Item 6] -0.008* [Item 7] -0.002* [Item 8] +0.013* [Item 9]
-0.011* [Item 10] +0.001* [Item 11] -0.008* [Item 12]
+0.983) uses all of the individual MSWS-12 item scores to
estimate EQ-5D index scores with a mean absolute error
(MAE) of 0.109 ± 0.096 [7]. Hawton and colleagues used
data from 560 people with MS in South West England
(SWIMS project; mean EQ-5D and MSWS-12 scores were
0.61 ± 0.25 and 60.1 ± 32.4, respectively), and similarly to
the abovementioned equation, found the OLS regression
using all individual MSWS-12 item scores (except for item
11, which was removed because of colinearity) to be the
best performing equation for calculating EQ-5D using the
UK scoring algorithm (which ranges from -0.594 to 1.0 on
a scale where 0.0 = death and 1.0 = perfect health), with
a MAE = 0.148, 95% confidence interval, 0.138 to 0.159
(EQ-5DUK = -0.0004282* [Item 1] -0.0029117* [Item 2]
-0.0213846* [Item 3] -0.0410001* [Item 4] +0.0086472*
[Item 5] -0.0340533* [Item 6] -0.0154952* [Item 7]
-0.0180406* [Item 8] +0.0004532* [Item 9] +0.0148398*
[Item 10] -0.004274* [Item 12] +0.9843433) [8].
Analyses included all patients from the study MS-F203
modified intent-to-treat (mITT) population (all random-
ized patients who received double-blind investigational
drug and who had at least one subsequent primary effi-
cacy assessment during the double-blind treatment
period) who had complete MSWS-12 data from at least
one baseline and one double-blind or follow-up visit [5].
We estimated mean change in health utility score from
baseline for each patient using the mapping equations
and reported the results as effect sizes (ESs) by calculat-
ing change in health utility score and dividing these by
the standard deviation (SD) of health utility score of all
patients at baseline.
The a priori definition of T25FW response in the MS-
F203 trial was the occurrence of faster walking speed for
at least three of the four visits during the double-blind
treatment period compared to the maximum speed for
any of the first five off-drug visits. However, previous re-
ports have suggested that a 20% improvement in
T25FW represents the minimally important clinical dif-
ference, or the smallest difference in an outcome meas-
ure that is perceived as beneficial by the patient [9-11].
Therefore, we utilized this latter definition for this ana-
lysis and categorized patients as a 20%-responder or
20%-nonresponder based on whether their mean of all
T25FW assessments during double-blind visits improved
by 20% or more from the mean of the pre-randomization
visits baseline. Differences in mean ESs were then com-
pared between 20%-responders or 20%-nonresponders,
and for dalfampridine-ER 20%-responders (random-
ized to receive dalfampridine-ER and achieved a ≥20%improvement), dalfampridine-ER 20%-nonresponders and
placebo patients. ES has been recommended in the litera-
ture as an appropriate benchmark for evaluating the mag-
nitude and clinically-relevant meaning of change in an
endpoint measure, with ESs of ≥0.2, ≥0.5, and ≥0.8 inter-
preted as small, medium, and large, respectively [11-14].
Categorical data were compared using chi-squared tests.
Continuous data were compared using either an unpaired
t-test or one-way analysis of variance (ANOVA) test with
Bonferroni post-hoc t-tests, where appropriate. A p-value
<0.05 was considered statistically significant in all situa-
tions. All analyses were conducted using SPSS version
17.0 (SPSS Inc., Chicago, IL, USA).
Results
In study MS-F203, a total of 301 patients were random-
ized, but one failed to take any double-blind treatment
and was thus excluded. Of the remaining 300, an addi-
tional 4 withdrew from the study before completing any
double-blind assessments, for a total of 296 patients in
the mITT population. As depicted in Table 1, the two
treatment groups were comparable in demographic
characteristics at baseline. Of these patients, 293 had at
least one pre-randomization MSWS-12 assessment, an
inclusion criterion specific to this analysis. Of these, 221
received dalfampridine-ER, of which 73 (33%) were cate-
gorized as 20%-responders, and 72 (33%) received pla-
cebo. The mean MSWS-12 ± SE scores at baseline for
dalfampridine-ER 20%-responders, dalfampridine-ER 20%-
nonresponders and placebo were 66.2 ± 2.32, 70.7 ± 1.69,
and 67.4 ± 2.78, respectively. Mean EQ-5D ± SE scores cal-
culated for these groups using the NA-derived equation
were 0.70 ± 0.006, 0.69 ± 0.005, and 0.70 ± 0.008, respect-
ively. No significant differences in MSWS-12 or EQ-5D
scores were observed between groups at baseline.
NA-derived equation results
Using the NA-derived equation, dalfampridine-ER 20%-
responders exhibited small improvements in health utility
vs. placebo starting at week six (visit 4; mean difference in
change score between groups: 0.028; mean difference in
ES between groups: 0.44, p = 0.002). (Table 2) These im-
provements were maintained at week 10 (visit 5; 0.026;
0.41, p = 0.009) and increased to moderate at week 14
(visit 6; 0.044; 0.71, p < 0.001). After treatment discontinu-
ation, improvements in health utility were no longer ap-
parent at week 16 (visit 7; 0.006; 0.10, p =NS) or week 18
(visit 8; 0.004, 0.06, p = NS). Similarly, dalfampridine-ER
20%-responders demonstrated small improvements in
health utility vs. dalfampridine-ER 20%-nonresponders
starting at week 6 (visit 4; 0.031; 0.49, p < 0.001). These in-
creased to moderate improvements at week 10 (visit 5;
0.032; 0.52, p < 0.001) and were maintained at week 14
(visit 6; 0.042; 0.67, p < 0.001). No improvements were
Table 1 Baseline characteristics of the modified intention-to-treat population from study MS-F203
Characteristic All patients Placebo Dalfampridine-ER 10 mg BID P-value
(N = 296) (N = 72) (N = 224)
Age, years (mean ± SE) 51.4 ± 0.51 50.9 ± 1.05 51.5 ± 0.58 0.50
Female gender, n (%) 201 (67.9) 43 (59.7) 158 (70.5) 0.11
MS Diagnosis Type 0.52
Primary progressive 44 (14.9) 14 (19.4) 30 (13.4)
Progressive relapsing 12 (4.1) 2 (2.8) 10 (4.5)
Relapsing remitting 82 (27.7) 21 (29.2) 61 (27.2)
Secondary progressive 158 (53.4) 35 (48.6) 123 (54.9)
Disease Duration, years (mean ± SE) 13.4 ± 0.48 12.7 ± 0.97 13.6 ± 0.55 0.38
EDSS score (mean ± SE) 5.8 ± 0.06 5.8 ± 0.13 5.8 ± 0.07 0.85
Range (Minimum, Maximum) (3, 7) (3, 7) (3, 7)
Timed 25-Foot Walk speed, feet/second (mean ± SE) 2.1 ± 0.04 2.1 ± 0.08 2.1 ± 0.05 0.85
BID twice daily, EDSS Expanded Disability Status Scale, ER extended-release, MS multiple sclerosis, SE standard error.










Mean ± SE Mean ± SE Mean ± SE
Average of placebo run-in and randomization
(Visits 0, 1, 2)
n = 72 n = 148 n = 73
EQ-5D at baseline 0.696 ± 0.008 0.691 ± 0.005 0.699 ± 0.006 NS NS
Week 2 (Visit 3) n = 70 n = 145 n = 71
Change from baseline, EQ-5D 0.002 ± 0.005 0.006 ± 0.004 0.017 ± 0.006 NS NS
Change from baseline, ES 0.033 ± 0.072 0.090 ± 0.069 0.267 ± 0.097
Week 6 (Visit 4) n = 70 n = 144 n = 71
Change from baseline, EQ-5D 0.002 ± 0.005 −0.002 ± 0.004 0.029 ± 0.006 0.002 <0.001
Change from baseline, ES 0.024 ± 0.082 −0.027 ± 0.063 0.464 ± 0.94
Week 10 (Visit 5) n = 68 n = 142 n = 68
Change from baseline, EQ-5D −0.001 ± 0.006 −0.008 ± 0.004 0.025 ± 0.006 0.009 <0.001
Change from baseline, ES −0.022 ± 0.089 −0.126 ± 0.069 0.391 ± 0.102
Week 14 (Visit 6) n = 70 n = 139 n = 70
Change from baseline, EQ-5D −0.014 ± 0.007 −0.012 ± 0.005 0.030 ± 0.008 <0.001 <0.001
Change from baseline, ES −0.227 ± 0.113 −0.196 ± 0.074 0.478 ± 0.124
Week 16 (Visit 7) n = 71 n = 144 n = 71
Change from baseline, EQ-5D −0.017 ± 0.007 −0.027 ± 0.005 −0.011 ± 0.007 NS NS
Change from baseline, ES −0.276 ± 0.105 −0.436 ± 0.083 −0.176 ± 0.113
Week 18 (Visit 8) n = 70 n = 140 n = 72
Change from baseline, EQ-5D −0.023 ± 0.006 −0.026 ± 0.005 −0.020 ± 0.007 NS NS
Change from baseline, ES −0.373 ± 0.092 −0.409 ± 0.078 −0.376 ± 0.053
DAL dalfampridine, EQ-5D Euroqol 5-Dimension, ES effect size, NR nonresponder, NS not significant, R responder, SE standard error.
See Figure 1A for graphical representation.
a20%-nonresponder or 20%-responder status based on whether the mean of all T25FW scores during double-blind visits improved by 20% or more from the
mean of the T25FW scores during pre-randomization visits.
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Figure 1 Effect sizes of change in EQ-5D by responder status and treatment group. Change in effect size for EQ-5D when stratified by
treatment group (dalfampridine-ER 20%-responder status or placebo) and 20%-responder status (≥20% percent increase in Timed 25-Foot Walk
speed or < 20%) during on-treatment visits 3-6 and off treatment visits 7/8. A, B) results using North American-derived equation; C, D) results
using United Kingdom-derived equation. *p < 0.05 versus D-ER nonresponders; †p < 0.05 versus placebo.
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week 18 (visit 8; 0.006; 0.092, p =NS) after treatment dis-
continuation. No significant differences were observed be-
tween dalfampridine-ER 20%-nonresponders and placebo
at any visit (p > 0.05 for all) (Figure 1A).
With the NA-derived equation, 20%-responders demon-
strated small improvements in health utility vs. 20%-nonre-
sponders starting at week two (visit 3; mean difference in
change score between groups: 0.016; mean difference in ES
between groups: 0.25, p = 0.016). (Table 3) Moderate im-
provements were maintained at week six (visit 4; 0.033;
0.52, p < 0.001), week 10 (visit 5; 0.035; 0.56, p < 0.001), and
week 14 (visit 6; 0.048; 0.76, p < 0.001). These improve-
ments began to decline after treatment discontinuation atweek 16 (visit 7; 0.020; 0.31, p = 0.013) and by week 18, sig-
nificant improvements in health utility no longer existed
(visit 8; 0.010; 0.16, p = 0.187) (Figure 1B).
UK-derived equation results
Using the UK-derived equation, dalfampridine-ER 20%-
responders demonstrated small improvements in health
utility vs. placebo starting at week two (visit 3; mean dif-
ference in change score between groups: 0.031; mean
difference in ES between groups: 0.49, p = 0.022).
(Table 4) Moderate improvements were apparent by
week six (visit 4; 0.035; 0.55, p = 0.009), maintained
through week 10 (visit 5; 0.037; 0.59, p = 0.009), and in-
creased to large improvements by week 14 (visit 6;
Table 3 Comparison of 20%-nonresponders vs. 20%-responders using the North American-derived equation
20%-nonrespondersa 20%-respondersa P-value
Mean ± SE Mean ± SE
Average of placebo run-in and randomization (Visits 0, 1, 2) n = 212 n = 81
EQ-5D at baseline 0.693 ± 0.005 0.698 ± 0.006 NS
Week 2 (Visit 3) n = 207 n = 79
Change from baseline, EQ-5D 0.003 ± 0.003 0.019 ± 0.006 0.02
Change from baseline, ES 0.052 ± 0.054 0.300 ± 0.088
Week 6 (Visit 4) n = 206 n = 79
Change from baseline, EQ-5D −0.002 ± 0.003 0.030 ± 0.005 <0.001
Change from baseline, ES −0.036 ± 0.051 0.483 ± 0.086
Week 10 (Visit 5) n = 202 n = 76
Change from baseline, EQ-5D −0.008 ± 0.004 0.027 ± 0.006 <0.001
Change from baseline, ES −0.128 ± 0.055 0.435 ± 0.094
Week 14 (Visit 6) n = 201 n = 78
Change from baseline, EQ-5D −0.016 ± 0.004 0.032 ± 0.007 <0.001
Change from baseline, ES −0.248 ± 0.062 0.515 ± 0.115
Week 16 (Visit 7) n = 207 n = 79
Change from baseline, EQ-5D −0.026 ± 0.004 −0.007 ± 0.007 0.01
Change from baseline, ES −0.418 ± 0.065 −0.104 ± 0.110
Week 18 (Visit 8) n = 203 n = 79
Change from baseline, EQ-5D −0.026 ± 0.004 −0.016 ± 0.007 NS
Change from baseline, ES −0.420 ± 0.061 −0.263 ± 0.108
EQ-5D Euroqol 5-Dimension, ES effect size, NS not significant SE standard error, T25FW Time 25 Foot Walk.
See Figure 1B for graphical representation.
a20%-nonresponder or 20%-responder status based on whether the mean of all T25FW scores during double-blind visits improved by 20% or more from the
mean of the T25FW scores during pre-randomization visits.
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improvements were no longer significant at week 16
(visit 7; 0.006; 0.010, p = NS) or week 18 (visit 8; -0.001;
-0.020, p = NS). Dalfampridine-ER 20%-responders dem-
onstrated small improvements in health utility vs.
dalfampridine-ER 20%-nonresponders starting at week
two (visit 3; 0.24; 0.39, p = 0.039). Moderate improve-
ments were observed at week six (visit 4; 0.47; 0.74, p <
0.001), maintained at week 10 (visit 5; 0.43; 0.68, p <
0.001), and increased to large improvements at week 14
(visit 6; 0.61; 0.97, p < 0.001). Significant improvements
were not seen at week 16 (visit 7; 0.021; 0.33, p = NS) or
week 18 (visit 8; 0.015; 0.23, p =NS) after discontinuation
of treatment. Dalfampridine-ER 20%-nonresponders did
not show improvements in health utility vs. placebo at any
visit (p > 0.05 for all) (Figure 1C).
Simlarly, 20%-responders demonstrated small im-
provements in health utility vs. 20%-nonresponders
starting at week two (visit 3; mean difference in change
score between groups: 0.030; mean difference in ES be-
tween groups: 0.47, p = 0.001). (Table 5) Moderate im-
provements were observed at week six (visit 4; 0.047;
0.75, p < 0.001), maintained at week 10 (visit 5; 0.046;0.72, p < 0.001), and increased to large improvements by
week 14 (visit 6; 0.067; 1.06, p < 0.001). After treatment
discontinuation, these improvements began to decline at
week 16 (visit 7; 0.022; 0.36, p = 0.034) and no significant
improvement was seen by week 18 (visit 8; 0.017; 0.26,
p = NS) (Figure 1D).Discussion
The Data from this post-hoc secondary analysis of the
double-blind, placebo-controlled clinical study MS-F203
demonstrate that dalfampridine-ER responders experi-
enced a small-to-moderate, but clinically-relevant im-
provement in health utility starting six weeks after
initiation of double-blind treatment, regardless of the
mapping equation used. These results are further sup-
ported by our additional analyses showing 20%-responders
performed better than non-responders, regardless of treat-
ment assignment. Furthermore, our analysis suggests that
these improvements in health utility were consistently
reported by dalfampridine-ER responders for an additional
8 weeks while on treatment; however, once double-blind
treatment was stopped, benefits began to dissipate.










Mean ± SE Mean ± SE Mean ± SE
Average of placebo run-in and randomization
(Visits 0, 1, 2)
n = 72 n = 148 n = 73
EQ-5D at baseline 0.574 ± 0.012 0.568 ± 0.008 0.579 ± 0.083 NS NS
Week 2 (Visit 3) n = 70 n = 145 n = 71
Change from baseline, EQ-5D 0.002 ± 0.007 0.008 ± 0.006 0.032 ± 0.008 0.022 0.04
Change from baseline, ES 0.025 ± 0.111 0.124 ± 0.094 0.512 ± 0.126
Week 6 (Visit 4) n = 70 n = 144 n = 71
Change from baseline, EQ-5D 0.007 ± 0.008 −0.005 ± 0.005 0.042 ± 0.085 0.009 <0.001
Change from baseline, ES 0.111 ± 0.119 −0.080 ± 0.084 0.665 ± 0.160
Week 10 (Visit 5) n = 68 n = 142 n = 68
Change from baseline, EQ-5D −0.006 ± 0.009 −0.012 ± 0.006 0.031 ± 0.010 0.009 <0.001
Change from baseline, ES −0.097 ± 0.140 −0.185 ± 0.089 0.495 ± 0.158
Week 14 (Visit 6) n = 70 n = 139 n = 70
Change from baseline, EQ-5D −0.021 ± 0.010 −0.020 ± 0.006 0.041 ± 0.012 <0.001 <0.001
Change from baseline, ES −0.337 ± 0.167 −0.319 ± 0.095 0.652 ± 0.188
Week 16 (Visit 7) n = 71 n = 144 n = 71
Change from baseline, EQ-5D −0.025 ± 0.009 −0.040 ± 0.007 −0.019 ± 0.010 NS NS
Change from baseline, ES −0.399 ± 0.148 −0.631 ± 0.107 −0.300 ± 0.155
Week 18 (Visit 8) n = 70 n = 140 n = 72
Change from baseline, EQ-5D −0.025 ± 0.010 −0.041 ± 0.006 −0.026 ± 0.010 NS NS
Change from baseline, ES −0.392 ± 0.151 −0.643 ± 0.103 −0.411 ± 0.160
DAL dalfampridine, EQ-5D Euroqol 5-Dimension, ES effect size, NR nonresponder, NS not significant, R responder, SE standard error.
See Figure 1C for graphical representation.
a20%-nonresponder or 20%-responder status based on whether the mean of all T25FW scores during double-blind visits improved by 20% or more from the
mean of the T25FW scores during pre-randomization visits.
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dalfampridine-ER 20%-responders, dalfampridine-ER 20%-
nonresponders, and placebo patients in our analysis
generally mimicked that seen in study MS-F203 for
the primary study endpoint of T25FW speed. In study
MS-F203, patients deemed T25FW responders to
dalfampridine (defined as a patient with a faster walk-
ing speed for at least three of the four visits during
the double-blind treatment period than the maximum
speed for any of the first five off-drug visits) showed
a sustained improvement in T25FW speed during the
treatment period starting at week two, which was com-
pletely reversed at the two-week and four-week off-drug
follow-up visits [5]. Improvements were greater in
dalfampridine-ER T25FW responders than in placebo and
dalfampridine-ER T25FW nonresponders at all on-drug
visits (p < 0.001 for all). Of note, we observed a one-visit
(up to four-week) delay in achieving statistically signifi-
cant improvements in health utility compared to T25FW
speed in study MS-F203. This may suggest that patients’
perceived improvement in HrQoL lags somewhat behindactual improvements in walking speed, or may simply
represent a statistical anomaly. Regardless, the similarities
between our health utility analysis and the T25FW data
provide some added validation of our results, particularly
when one keeps in mind that T25FW is an unique mea-
sure of mobility from the MSWS-12 from which our
EQ-5D scores were derived.
While the aim of this analysis was not to compare the
results of the NA- and UK-derived equations, our ana-
lysis did demonstrate they yielded somewhat similar
health utility when we applied to data from study MS-
F203. That being said, important differences in these
equations’ initial derivation databases may partially ex-
plain the differences in comparative effect estimates seen
in our analysis with these two equations. The NA map-
ping equation was derived using data from a large cohort
of NA (US and Canada) patients (n = 3,505) included in
the NARCOMS database; the UK equation from Hawton
and colleagues was derived in a significantly smaller co-
hort of MS patients in South West England (SWIMS pro-
ject, n = 560). Moreover, the UK–based SWIMS database
Table 5 Comparison of 20%-nonresponders vs. 20%-responders using the United Kingdom-derived equation
20%-nonrespondersa 20%-respondersa P-value
Mean ± SE Mean ± SE
Average of placebo run-in and randomization (Visits 0, 1, 2) n = 212 n = 81
EQ-5D at baseline 0.570 ± 0.007 0.577 ± 0.009 NS
Week 2 (Visit 3) n = 207 n = 79
Change from baseline, EQ-5D 0.004 ± 0.005 0.034 ± 0.007 0.001
Change from baseline, ES 0.067 ± 0.075 0.535 ± 0.115
Week 6 (Visit 4) n = 206 n = 79
Change from baseline, EQ-5D −0.004 ± 0.004 0.044 ± 0.009 <0.001
Change from baseline, ES −0.055 ± 0.070 0.694 ± 0.144
Week 10 (Visit 5) n = 202 n = 76
Change from baseline, EQ-5D −0.012 ± 0.005 0.033 ± 0.009 <0.001
Change from baseline, ES −0.195 ± 0.076 0.529 ± 0.144
Week 14 (Visit 6) n = 201 n = 78
Change from baseline, EQ-5D −0.024 ± 0.005 0.043 ± 0.011 <0.001
Change from baseline, ES −0.376 ± 0.084 0.682 ± 0.173
Week 16 (Visit 7) n = 207 n = 79
Change from baseline, EQ-5D −0.037 ± 0.006 −0.015 ± 0.010 0.03
Change from baseline, ES −0.590 ± 0.087 −0.232 ± 0.150
Week 18 (Visit 8) n = 203 n = 79
Change from baseline, EQ-5D −0.038 ± 0.005 −0.021 ± 0.010 NS
Change from baseline, ES −0.596 ± 0.086 −0.331 ± 0.153
EQ-5D Euroqol 5-Dimension, ES effect size, NS not significant, SE standard error, T25FW Timed 25 Foot Walk.
See Figure 1D for graphical representation.
a20%-nonresponder or 20%-responder status based on whether the mean of all T25FW scores during double-blind visits improved by 20% or more from the
mean of the T25FW scores during pre-randomization visits.
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system for the EQ-5D, which has a much wider range of
health state values (-0.594 for the worst possible state to
1.00 for the best) than the US scoring algorithm used by
NARCOMS (-0.109 for the worst health state to 1.00 for
the best) [15]. According to guidance on health state util-
ity mapping from the National Institute for Health and
Clinical Excellence’s (NICE’s) it is important there be simi-
larity between characteristics of the estimation and target
samples in order for the findings of any future analysis to
be valid [16]. The NA-derived equation not only used MS
patients from the same geographic region as MS-F203,
North America, but was also shown to be most precise
(MAE of 0.087 ± 0.061) in patients with a Patient-
Determined Disease Steps (PDDS) between 3 and 6 (cor-
relating with an EDSS score of 4-6.5), the same degree of
mobility impairment seen in MS-F203 (mean EDSS of 5.8)
[3]. Thus, it would seem most appropriate to put some-
what greater weight on health utility values and effect sizes
for study MS-F203 stemming from the NA-derived equa-
tion. Though beyond the scope of this analysis, future re-
search into the cost-effectiveness of dalfampridine-ER can
now be accomplished by utilizing the results of thisanalysis. It is important to note, health utility values
reported here should be carefully selected based upon
country perspective of future cost-effectiveness analyses.
There are some limitations to our analysis worth further
discussion. First, as highlighted in the NICE Decision Sup-
port Unit guidance, mapping is “at best, a second-best solu-
tion” to the direct collection of EQ-5D values [16]. However,
as no health utility values were collected as part of the two
Phase 3 clinical trials of dalfampridine-ER, our data repre-
sents the best estimates of the drug’s effect on health utility
currently available. Moreover, since no mapping equation is
perfect, we used both available equations to map the
MSWS-12 to the EQ-5D available at the time. The fact that
when both equations were applied to dalfampridine-ER clin-
ical trial data yield similar results lends credence to our
overall conclusion that dalfampridine-ER responders realize
an improvement in health utility. Next, the post-hoc nature
of data analysis from study MS-F203 lends itself to the pos-
sibility of type two error in our results. As this was not the
primary, or even a prospectively defined, analysis of data
from study MS-F203, inadequate sample sizes may have
precluded us from showing clinically important differences
at all time points.
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Regardless of the mapping equation used, results suggest
dalfampridine-ER response is associated with a note-
worthy improvement in health utility in MS patients.
The UK-derived equation resulted in larger estimates of
improvement than the NA-derived equation. The results
presented in the current analysis may aid decision- and
policy-makers in coverage decisions and aid investigators
in designing and conducting future research into the
clinical- and cost-effectiveness of dalfampridine-ER.
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